Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective
2008
New EU Regulations for Pediatric Drug Development
Commentary
Author Information
Author(s): Philippe Auby
Primary Institution: Lundbeck SAS
Hypothesis
The new European Paediatric Regulation will improve children's access to safe and effective medications.
Conclusion
The European Paediatric Regulation is a significant step towards ensuring that children have access to medications that are specifically studied and approved for their use.
Supporting Evidence
- Many medicines for children are prescribed off-label, which can be unsafe.
- The new EU legislation requires pharmaceutical companies to conduct studies for pediatric use.
- The regulation aims to improve the health of children in Europe through better research.
Takeaway
New rules in Europe will help make sure that medicines for kids are tested properly so they can be safe and effective.
Limitations
The article discusses the challenges and hurdles in conducting pediatric research, including ethical and practical issues.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website